NICE does not recommend ofatumumab for people with chronic lymphocytic leukaemia that is refractory to treatment with two other drugs called fludarabine and alemtuzumab.

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.

It was not clear from the evidence whether ofatumumab provides enough benefit to patients to justify its high cost, and it did not qualify for special consideration (because of doubts about the evidence), so NICE did not recommend it.

  • National Institute for Health and Care Excellence (NICE) accreditation logo